Bacitracin-neomycin-polymyxin + Cidofovir

MediHelp rates the interaction as major. Bacitracin-neomycin-polymyxin and Cidofovir can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Systemic polymyxin B, neomycin and bacitracin are nephrotoxic, and cidofovir causes dose-limiting proximal tubular kidney injury. Combined exposure may cause severe renal damage, and cidofovir labeling contraindicates concurrent nephrotoxic agents. Risk applies mainly to systemic or heavily absorbed use rather than small topical applications.

MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid systemic or heavily absorbed use of these antibiotics during and shortly after cidofovir therapy. If unavoidable, monitor serum creatinine and urine protein closely.

MediHelp also lists interactions of Bacitracin-neomycin-polymyxin with, for example, Allogeneic cultured keratinocytes / fibroblasts in bovine collagen, Atracurium, Capreomycin. The full list is on the Bacitracin-neomycin-polymyxin page.